Advances of nucleosome in diagnosis and treatment of colorectal cancer_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

HUANG Yuwei ^1,2 , AN Limin ^1,2 , LI Li ¹ ,  WANG Xiaodong ¹

1. Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu 610041, P. R. China;
2. West China School of Medicine, Sichuan University, Chengdu 610041, P. R. China;

Corresponding author：

WANG Xiaodong, Email: lockwan@163.com

Keywords：

colorectal cancer; nucleosome; biomarker; review

DOI：

10.7507/1007-9424.202009010

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To summarize the significance of nucleosome and its omics in the occurrence, development, screening, treatment, and prognosis of colorectal cancer.Method This article reviewed and analyzed the literatures about significance of nucleosome in diagnosis and treatment of colorectal cancer in recent years.Results The changes of circulating nucleosome and its omics in patients with colorectal cancer were more significant than those in normal persons, and these changes were closely related to the occurrence and development of colorectal cancer, as well as early screening, evaluation of therapeutic effect, and prognosis. The present study found this association only and failed to elucidate its specific mechanism.Conclusions Nucleosome and its omics may have clinical value in the screening, treatment, and prognosis evaluation of colorectal cancer. Compared with other serum markers, nucleosome has some advantages in the early screening of colorectal cancer.

Citation： HUANG Yuwei, AN Limin, LI Li, WANG Xiaodong. Advances of nucleosome in diagnosis and treatment of colorectal cancer. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2021, 28(6): 826-830. doi: 10.7507/1007-9424.202009010 Copy

1.	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018, 68(6): 394-424.
2.	Kinzler KW, Vogelstein B. Colorectal tumors//Vogelstein B, Kinzler KW. The genetic basis of human cancer. McGraw-Hill: New York, 1998.
3.	Khorasanizadeh S. The nucleosome: from genomic organization to genomic regulation. Cell, 2004, 116(2): 259-272.
4.	Luger K. Structure and dynamic behavior of nucleosomes. Curr Opin Genet Dev, 2003, 13(2): 127-135.
5.	Reis AH, Vargas FR, Lemos B. Biomarkers of genome instability and cancer epigenetics. Tumour Biol, 2016, 37(10): 13029-13038.
6.	Barault L, Amatu A, Siravegna G, et al. Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer. Gut, 2018, 67(11): 1995-2005.
7.	Trejo-Becerril C, Pérez-Cárdenas E, Treviño-Cuevas H, et al. Circulating nucleosomes and response to chemotherapy: an in vitro, in vivo and clinical study on cervical cancer patients. Int J Cancer, 2003, 104(6): 663-668.
8.	Holdenrieder S, Stieber P, Bodenmüller H, et al. Nucleosomes in serum of patients with benign and malignant diseases. Int J Cancer, 2001, 95(2): 114-120.
9.	Holdenrieder S, Nagel D, Schalhorn A, et al. Clinical relevance of circulating nucleosomes in cancer. Ann N Y Acad Sci, 2008, 1137: 180-189.
10.	Rasmussen L, Christensen IJ, Herzog M, et al. Circulating cell-free nucleosomes as biomarkers for early detection of colorectal cancer. Oncotarget, 2017, 9(12): 10247-10258.
11.	Al-Shuneigat JM, Mahgoub SS, Huq F. Colorectal carcinoma: nucleosomes, carcinoembryonic antigen and CA 19-9 as apoptotic markers; a comparative study. J Biomed Sci, 2011, 18(1): 50.
12.	Holdenrieder S, Dharuman Y, Standop J, et al. Novel serum nucleosomics biomarkers for the detection of colorectal cancer. Anticancer Res, 2014, 34(5): 2357-2362.
13.	Schreuders EH, Ruco A, Rabeneck L, et al. Colorectal cancer screening: a global overview of existing programmes. Gut, 2015, 64(10): 1637-1649.
14.	Hewitson P, Glasziou P, Watson E, et al. Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. Am J Gastroenterol, 2008, 103(6): 1541-1549.
15.	Jin P, Kang Q, Wang X, et al. Performance of a second-generation methylated SEPT9 test in detecting colorectal neoplasm. J Gastroenterol Hepatol, 2015, 30(5): 830-833.
16.	Ulz P, Perakis S, Zhou Q, et al. Inference of transcription factor binding from cell-free DNA enables tumor subtype prediction and early detection. Nat Commun, 2019, 10(1): 4666.
17.	Schwarzenbach H, Hoon DS, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer, 2011, 11(6): 426-437.
18.	Druliner BR, Vera D, Johnson R, et al. Comprehensive nucleosome mapping of the human genome in cancer progression. Oncotarget, 2016, 7(12): 13429-13445.
19.	Holdenrieder S, Stieber P. Clinical use of circulating nucleosomes. Crit Rev Clin Lab Sci, 2009, 46(1): 1-24.
20.	Jahr S, Hentze H, Englisch S, et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res, 2001, 61(4): 1659-1665.
21.	Deligezer U, Akisik EE, Erten N, et al. Sequence-specific histone methylation is detectable on circulating nucleosomes in plasma. Clin Chem, 2008, 54(7): 1125-1131.
22.	Deligezer U, Yaman F, Darendeliler E, et al. Post-treatment circulating plasma BMP6 mRNA and H3K27 methylation levels discriminate metastatic prostate cancer from localized disease. Clin Chim Acta, 2010, 411(19-20): 1452-1456.
23.	Gezer U, Yörüker EE, Keskin M, et al. Histone methylation marks on circulating nucleosomes as novel blood-based biomarker in colorectal cancer. Int J Mol Sci, 2015, 16(12): 29654-29662.
24.	Gezer U, Ustek D, Yörüker EE, et al. Characterization of H3K9me3- and H4K20me3-associated circulating nucleosomal DNA by high-throughput sequencing in colorectal cancer. Tumour Biol, 2013, 34(1): 329-336.
25.	Li J, Ma S, Lin T, et al. Comprehensive analysis of therapy-related messenger RNAs and long noncoding RNAs as novel biomarkers for advanced colorectal cancer. Front Genet, 2019, 10: 803.
26.	Cristiano S, Leal A, Phallen J, et al. Genome-wide cell-free DNA fragmentation in patients with cancer. Nature, 2019, 570(7761): 385-389.
27.	Gezer U, Mert U, Ozgür E, et al. Correlation of histone methyl marks with circulating nucleosomes in blood plasma of cancer patients. Oncol Lett, 2012, 3(5): 1095-1098.
28.	Rahier JF, Druez A, Faugeras L, et al. Circulating nucleosomes as new blood-based biomarkers for detection of colorectal cancer. Clin Epigenetics, 2017, 9: 53.
29.	Holdenrieder S, Stieber P, von Pawel J, et al. Circulating nucleosomes predict the response to chemotherapy in patients with advanced non-small cell lung cancer. Clin Cancer Res, 2004, 10(18 Pt 1): 5981-5987.
30.	Holdenrieder S, von Pawel J, Dankelmann E, et al. Nucleosomes, ProGRP, NSE, CYFRA 21-1, and CEA in monitoring first-line chemotherapy of small cell lung cancer. Clin Cancer Res, 2008, 14(23): 7813-7821.
31.	Kremer A, Wilkowski R, Holdenrieder S, et al. Nucleosomes in pancreatic cancer patients during radiochemotherapy. Tumour Biol, 2005, 26(1): 44-49.
32.	Holdenrieder S, Holubec L Jr, Topolcan O, et al. Circulating nucleosomes and cytokeratin 19-fragments in patients with colorectal cancer during chemotherapy. Anticancer Res, 2005, 25(3A): 1795-1801.
33.	Kremer A, Holdenrieder S, Stieber P, et al. Nucleosomes in colorectal cancer patients during radiochemotherapy. Tumour Biol, 2006, 27(5): 235-242.
34.	Fahmueller YN, Nagel D, Hoffmann RT, et al. Predictive and prognostic value of circulating nucleosomes and serum biomarkers in patients with metastasized colorectal cancer undergoing Selective Internal Radiation Therapy. BMC Cancer, 2012, 12: 5.
35.	Gurdal N, Fayda M, Alishev N, et al. Neoadjuvant volumetric modulated arc therapy in rectal cancer and the correlation of pathological response with diffusion-weighted MRI and apoptotic markers. Tumori, 2018, 104(4): 266-272.
36.	Holdenrieder S, Mueller S, Stieber P. Stability of nucleosomal DNA fragments in serum. Clin Chem, 2005, 51(6): 1026-1029.
37.	Chen X, Song N, Matsumoto K, et al. High expression of trimethylated histone H3 at lysine 27 predicts better prognosis in non-small cell lung cancer. Int J Oncol, 2013, 43(5): 1467-1480.
38.	Holm K, Grabau D, Lövgren K, et al. Global H3K27 trimethylation and EZH2 abundance in breast tumor subtypes. Mol Oncol, 2012, 6(5): 494-506.
39.	Benard A, van de Velde CJ, Lessard L, et al. Epigenetic status of LINE-1 predicts clinical outcome in early-stage rectal cancer. Br J Cancer, 2013, 109(12): 3073-3083.
40.	Benard A, Goossens-Beumer IJ, van Hoesel AQ, et al. Prognostic value of polycomb proteins EZH2, BMI1 and SUZ12 and histone modification H3K27me3 in colorectal cancer. PLoS One, 2014, 9(9): e108265.
41.	Gimeno-Valiente F, Riffo-Campos ÁL, Vallet-Sánchez A, et al. ZNF518B gene up-regulation promotes dissemination of tumour cells and is governed by epigenetic mechanisms in colorectal cancer. Sci Rep, 2019, 9(1): 9339.
42.	Wang HC, Chou CL, Yang CC, et al. Over-expression of CHD4 is an independent biomarker of poor prognosis in patients with rectal cancers receiving concurrent chemoradiotherapy. Int J Mol Sci, 2019, 20(17): 4087.
43.	Goossens-Beumer IJ, Benard A, van Hoesel AQ, et al. Age-dependent clinical prognostic value of histone modifications in colorectal cancer. Transl Res, 2015, 165(5): 578-588.

1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018, 68(6): 394-424.
2. Kinzler KW, Vogelstein B. Colorectal tumors//Vogelstein B, Kinzler KW. The genetic basis of human cancer. McGraw-Hill: New York, 1998.
3. Khorasanizadeh S. The nucleosome: from genomic organization to genomic regulation. Cell, 2004, 116(2): 259-272.
4. Luger K. Structure and dynamic behavior of nucleosomes. Curr Opin Genet Dev, 2003, 13(2): 127-135.
5. Reis AH, Vargas FR, Lemos B. Biomarkers of genome instability and cancer epigenetics. Tumour Biol, 2016, 37(10): 13029-13038.
6. Barault L, Amatu A, Siravegna G, et al. Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer. Gut, 2018, 67(11): 1995-2005.
7. Trejo-Becerril C, Pérez-Cárdenas E, Treviño-Cuevas H, et al. Circulating nucleosomes and response to chemotherapy: an in vitro, in vivo and clinical study on cervical cancer patients. Int J Cancer, 2003, 104(6): 663-668.
8. Holdenrieder S, Stieber P, Bodenmüller H, et al. Nucleosomes in serum of patients with benign and malignant diseases. Int J Cancer, 2001, 95(2): 114-120.
9. Holdenrieder S, Nagel D, Schalhorn A, et al. Clinical relevance of circulating nucleosomes in cancer. Ann N Y Acad Sci, 2008, 1137: 180-189.
10. Rasmussen L, Christensen IJ, Herzog M, et al. Circulating cell-free nucleosomes as biomarkers for early detection of colorectal cancer. Oncotarget, 2017, 9(12): 10247-10258.
11. Al-Shuneigat JM, Mahgoub SS, Huq F. Colorectal carcinoma: nucleosomes, carcinoembryonic antigen and CA 19-9 as apoptotic markers; a comparative study. J Biomed Sci, 2011, 18(1): 50.
12. Holdenrieder S, Dharuman Y, Standop J, et al. Novel serum nucleosomics biomarkers for the detection of colorectal cancer. Anticancer Res, 2014, 34(5): 2357-2362.
13. Schreuders EH, Ruco A, Rabeneck L, et al. Colorectal cancer screening: a global overview of existing programmes. Gut, 2015, 64(10): 1637-1649.
14. Hewitson P, Glasziou P, Watson E, et al. Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. Am J Gastroenterol, 2008, 103(6): 1541-1549.
15. Jin P, Kang Q, Wang X, et al. Performance of a second-generation methylated SEPT9 test in detecting colorectal neoplasm. J Gastroenterol Hepatol, 2015, 30(5): 830-833.
16. Ulz P, Perakis S, Zhou Q, et al. Inference of transcription factor binding from cell-free DNA enables tumor subtype prediction and early detection. Nat Commun, 2019, 10(1): 4666.
17. Schwarzenbach H, Hoon DS, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer, 2011, 11(6): 426-437.
18. Druliner BR, Vera D, Johnson R, et al. Comprehensive nucleosome mapping of the human genome in cancer progression. Oncotarget, 2016, 7(12): 13429-13445.
19. Holdenrieder S, Stieber P. Clinical use of circulating nucleosomes. Crit Rev Clin Lab Sci, 2009, 46(1): 1-24.
20. Jahr S, Hentze H, Englisch S, et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res, 2001, 61(4): 1659-1665.
21. Deligezer U, Akisik EE, Erten N, et al. Sequence-specific histone methylation is detectable on circulating nucleosomes in plasma. Clin Chem, 2008, 54(7): 1125-1131.
22. Deligezer U, Yaman F, Darendeliler E, et al. Post-treatment circulating plasma BMP6 mRNA and H3K27 methylation levels discriminate metastatic prostate cancer from localized disease. Clin Chim Acta, 2010, 411(19-20): 1452-1456.
23. Gezer U, Yörüker EE, Keskin M, et al. Histone methylation marks on circulating nucleosomes as novel blood-based biomarker in colorectal cancer. Int J Mol Sci, 2015, 16(12): 29654-29662.
24. Gezer U, Ustek D, Yörüker EE, et al. Characterization of H3K9me3- and H4K20me3-associated circulating nucleosomal DNA by high-throughput sequencing in colorectal cancer. Tumour Biol, 2013, 34(1): 329-336.
25. Li J, Ma S, Lin T, et al. Comprehensive analysis of therapy-related messenger RNAs and long noncoding RNAs as novel biomarkers for advanced colorectal cancer. Front Genet, 2019, 10: 803.
26. Cristiano S, Leal A, Phallen J, et al. Genome-wide cell-free DNA fragmentation in patients with cancer. Nature, 2019, 570(7761): 385-389.
27. Gezer U, Mert U, Ozgür E, et al. Correlation of histone methyl marks with circulating nucleosomes in blood plasma of cancer patients. Oncol Lett, 2012, 3(5): 1095-1098.
28. Rahier JF, Druez A, Faugeras L, et al. Circulating nucleosomes as new blood-based biomarkers for detection of colorectal cancer. Clin Epigenetics, 2017, 9: 53.
29. Holdenrieder S, Stieber P, von Pawel J, et al. Circulating nucleosomes predict the response to chemotherapy in patients with advanced non-small cell lung cancer. Clin Cancer Res, 2004, 10(18 Pt 1): 5981-5987.
30. Holdenrieder S, von Pawel J, Dankelmann E, et al. Nucleosomes, ProGRP, NSE, CYFRA 21-1, and CEA in monitoring first-line chemotherapy of small cell lung cancer. Clin Cancer Res, 2008, 14(23): 7813-7821.
31. Kremer A, Wilkowski R, Holdenrieder S, et al. Nucleosomes in pancreatic cancer patients during radiochemotherapy. Tumour Biol, 2005, 26(1): 44-49.
32. Holdenrieder S, Holubec L Jr, Topolcan O, et al. Circulating nucleosomes and cytokeratin 19-fragments in patients with colorectal cancer during chemotherapy. Anticancer Res, 2005, 25(3A): 1795-1801.
33. Kremer A, Holdenrieder S, Stieber P, et al. Nucleosomes in colorectal cancer patients during radiochemotherapy. Tumour Biol, 2006, 27(5): 235-242.
34. Fahmueller YN, Nagel D, Hoffmann RT, et al. Predictive and prognostic value of circulating nucleosomes and serum biomarkers in patients with metastasized colorectal cancer undergoing Selective Internal Radiation Therapy. BMC Cancer, 2012, 12: 5.
35. Gurdal N, Fayda M, Alishev N, et al. Neoadjuvant volumetric modulated arc therapy in rectal cancer and the correlation of pathological response with diffusion-weighted MRI and apoptotic markers. Tumori, 2018, 104(4): 266-272.
36. Holdenrieder S, Mueller S, Stieber P. Stability of nucleosomal DNA fragments in serum. Clin Chem, 2005, 51(6): 1026-1029.
37. Chen X, Song N, Matsumoto K, et al. High expression of trimethylated histone H3 at lysine 27 predicts better prognosis in non-small cell lung cancer. Int J Oncol, 2013, 43(5): 1467-1480.
38. Holm K, Grabau D, Lövgren K, et al. Global H3K27 trimethylation and EZH2 abundance in breast tumor subtypes. Mol Oncol, 2012, 6(5): 494-506.
39. Benard A, van de Velde CJ, Lessard L, et al. Epigenetic status of LINE-1 predicts clinical outcome in early-stage rectal cancer. Br J Cancer, 2013, 109(12): 3073-3083.
40. Benard A, Goossens-Beumer IJ, van Hoesel AQ, et al. Prognostic value of polycomb proteins EZH2, BMI1 and SUZ12 and histone modification H3K27me3 in colorectal cancer. PLoS One, 2014, 9(9): e108265.
41. Gimeno-Valiente F, Riffo-Campos ÁL, Vallet-Sánchez A, et al. ZNF518B gene up-regulation promotes dissemination of tumour cells and is governed by epigenetic mechanisms in colorectal cancer. Sci Rep, 2019, 9(1): 9339.
42. Wang HC, Chou CL, Yang CC, et al. Over-expression of CHD4 is an independent biomarker of poor prognosis in patients with rectal cancers receiving concurrent chemoradiotherapy. Int J Mol Sci, 2019, 20(17): 4087.
43. Goossens-Beumer IJ, Benard A, van Hoesel AQ, et al. Age-dependent clinical prognostic value of histone modifications in colorectal cancer. Transl Res, 2015, 165(5): 578-588.

Previous Article
Current status and research progress in the assessment of anal function after transanal total mesorectal resection
Next Article
Risk factors associated with carotid endarterectomy

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Advances of nucleosome in diagnosis and treatment of colorectal cancer

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content